TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04058717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Nicotine Content research cigarettes
Description: Research cigarettes with 11.6 mg nicotine/cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Nicotine Content research cigarettes
Description: Research cigarettes with 11.6 mg nicotine/cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Nicotine e-cigarette
Description: E-cigarette containing high nicotine e-liquid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Nicotine e-cigarette
Description: E-cigarette containing high nicotine e-liquid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content research cigarettes
Description: Research cigarettes with 0.2 mg nicotine/cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content research cigarettes
Description: Research cigarettes with 0.2 mg nicotine/cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zero Nicotine e-cigarette
Description: E-cigarette containing zero nicotine e-liquid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zero Nicotine e-cigarette
Description: E-cigarette containing zero nicotine e-liquid
Study: NCT06526676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Alpha TX2 Stent Graft, Cook Zenith TX2, and Cook Zenith Fenestrated Stent Graft
Description: Physician-modified stent grafts that utilizes multiple stent grafts with a combination of fenestrations and/or branches

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Alpha TX2 Stent Graft, Cook Zenith TX2, and Cook Zenith Fenestrated Stent Graft
Description: Physician-modified stent grafts that utilizes multiple stent grafts with a combination of fenestrations and/or branches

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Alpha TX2 Stent Graft, Cook Zenith TX2, and Cook Zenith Fenestrated Stent Graft
Description: Physician-modified stent grafts that utilizes multiple stent grafts with a combination of fenestrations and/or branches
Study: NCT05742685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement Learning
Description: Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
Study: NCT05975840

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU Q-PAN H5N8 Formulation 1
Description: Participants receive two doses of the FLU Q-PAN H5N8 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU Q-PAN H5N8 Formulation 1
Description: Participants receive two doses of the FLU Q-PAN H5N8 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS03B
Description: Participants receive two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS03B
Description: Participants receive two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS03A
Description: Participants receive two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS03A
Description: Participants receive two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU Q-PAN H5N8 Formulation 2
Description: Participants receive two doses of the FLU Q-PAN H5N8 Formulation 2 vaccine by intramuscular injection in the non dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU Q-PAN H5N8 Formulation 2
Description: Participants receive two doses of the FLU Q-PAN H5N8 Formulation 2 vaccine by intramuscular injection in the non dominant arm.
Study: NCT05226624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rooming-in care
Description: Implementation of Rooming-in model of care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline standard of care
Description: Baseline standard of care
Study: NCT05891379

Intervention type: DRUG
Intervention: Inebilizumab
Description: Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.

Intervention type: DRUG
Intervention: oral immunosuppressant
Description: Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.
Study: NCT04780061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU
Description: This is a loading dose of Vitamin D. Vitamin D (cholecalciferol \[vitamin D3\]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C/Zinc
Description: This is a combination of Vitamin C and Zinc. Vitamin C (ascorbic acid, ascorbate) is a water-soluble vitamin that naturally occurs in many foods and is sold as a dietary supplement. It is required for the functioning of several enzymes and is important for the immune system. Zinc is one of the most abundant essential trace elements in the human body and is required for the function of several hundred enzymes and transcription factors.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2/D
Description: This is a combination of Vitamin K2 (menaquinone-7) and vitamin D. Vitamin K (menaquinone-7 \[vitamin K2\]) is a fat-soluble vitamin found in foods and sold as a dietary supplement. Vitamin K plays a large role in synthesizing coagulation factors in the blood, and vitamin K deficiency has been associated with uncontrolled bleeding. Vitamin K1 (phylloquinone) is an alternate form of vitamin K found in foods and supplements; however, vitamin K2 has a better absorption profile50 and additionally plays a role in bone metabolism controlling the binding of calcium, especially in older adults, where it attenuates the rate of bone loss

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose Capsule
Description: Placebo equivalent of Vitamin C/Zinc and Vitamin D3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medium Chain Triglyceride Oil
Description: Placebo equivalent of Vitamin K2/D
Study: NCT04782713

Intervention type: OTHER
Group type: OTHER
Intervention: Completing surveys
Description: Completing surveys at baseline, 3, 6, 9, and 12 months
Study: NCT06585098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: game based learning
Description: The students in the intervention group were informed by the researcher, and the students who met the research participation criteria and volunteered to participate in the research filled out the Informed Consent Form (Annex 1) and downloaded the prepared game-based virtual reality application by entering the prepared website and using their username and password for a period of 1 week. They were asked to play with. After one week, students in the intervention group were invited to a simulation-based training application in groups of seven. In addition, the game was played at least once by the students in the intervention group under the supervision of the researcher.
Study: NCT06295185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application MARO
Description: It is a mental healthcare application aim to improve mental health.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham application
Description: It is a sham application in order to control spill over bias.
Study: NCT05279196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadriceps microbiopsy and blood collection
Description: Microbiopsy of the quadriceps muscle using a needle, Tru-cut biopsy, associated with a blood sampling at the start and after 6 months of a muscle strengthening training program
Study: NCT06362824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: De Pie Intervention
Description: Participants are guided by a health coach trained in motivational interviewing through 6 biweekly phone sessions. Each session involves reviewing goals and problem-solving barriers from the prior 2 weeks experience; covering a topic related to Step 1 goals (or Step 2 goals if they pass the safety assessment) such as how to enjoy movement, social support, and using your surroundings; and setting goals and an action plan for the following two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparison Group: Healthy Actions And Lifestyles To Avoid Dementia (HALT-AD)
Description: Those in the active comparison program will receive no additional health coaching sessions. They will work through the HALT-AD content at their own pace, setting goals in the online platform as they go.
Study: NCT06585397

Intervention type: OTHER
Intervention: Grup 1
Description: Within the framework of ICF, the Modified Ashworth Scale, the Manual Ability Classification System and the Functional Independence Measure for Children will be applied to 20 quadriparetic children with CP.
Study: NCT05881304

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized research e-cigarette (SREC)
Description: Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized research e-cigarette (SREC)
Description: Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.
Study: NCT05750264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg of IV ibuprofen
Study: NCT06435351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Removal of white blood cells (leukocytes) from the blood. The dendritic cells are harvested from the white blood cells that are collected and trained to recognize the specific abnormal proteins found in the tumor sample.~One needle is inserted in each arm. An apheresis machine removes blood from the vein in one arm, separates and retains the leukocytes from the blood, and then returns the rest of the blood to the other arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell (DC) Vaccine
Description: The vaccine will be given intranodally (inguinal or axillary) under ultrasound guidance using a dose of 40-50 million cells three times spaced 2 weeks apart for the initial priming sequence.~3 doses of the priming vaccines are given once every 2 weeks. 2 booster shots (if available) will be given 6 months and 12 months following completion of initial priming vaccines.
Study: NCT04809987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Gait
Description: The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where a video of treadmill gait of a person will be projected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Gait
Description: The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where a video of treadmill gait of a person will be projected.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical Exercise
Description: Specific gait exercise was conducted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Specific gait exercise was conducted.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Documental projection
Description: The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Documental projection
Description: The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed.
Study: NCT04907799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily caloric restriction
Description: Weight loss based on daily caloric restriction and increased physical activity

Intervention type: OTHER
Group type: OTHER
Intervention: Standard advice control
Description: Initial nutrition consultation without subsequent counseling
Study: NCT05602454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Heart Failure Medication Titration
Description: Story Health Platform, which is a remote, digital tool that provides treating clinicians collected data to make clinical decisions regarding heart failure medication titration.
Study: NCT05520255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007
Description: 18F-PSMA-1007 intravenous injection
Study: NCT06210724

Intervention type: DIAGNOSTIC_TEST
Intervention: Faecal immunochemical test for haemoglobin, faecal calprotectin, faecal microbiome
Description: Faecal samples to be collected by patients at home and delivered via post to a bowel cancer screening hub for analysis
Study: NCT05880134

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional posterior nerve neurectomy
Description: A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cartilage graft reinforcement after posterior nerve neurectomy
Description: A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results.~then harvest cartilage from nasal septum and refashion it around sphenopalatine bundle to prevent nerve re-innervation~The mucoperiosteal flaps are repositioned . No nasal packing is required. Patients are discharged on the same day
Study: NCT05580653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled feeding study of beef and/or pinto beans
Description: Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (beef, pinto beans, and half beef/half pinto beans) completed in random order.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled feeding study of beef and/or pinto beans
Description: Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (beef, pinto beans, and half beef/half pinto beans) completed in random order.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled feeding study of beef and/or pinto beans
Description: Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (beef, pinto beans, and half beef/half pinto beans) completed in random order.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled feeding study of eggs and/or black beans
Description: Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (eggs, black beans, and half eggs/half black beans) completed in random order.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled feeding study of eggs and/or black beans
Description: Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (eggs, black beans, and half eggs/half black beans) completed in random order.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled feeding study of eggs and/or black beans
Description: Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (eggs, black beans, and half eggs/half black beans) completed in random order.
Study: NCT05690724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitocholine™ or Placebo
Description: Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mitocholine™ or Placebo
Description: Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.
Study: NCT05417022

Intervention type: DEVICE
Intervention: Diamondback 360TM orbital atherectomy system
Description: Use of the Diamondback 360TM orbital atherectomy system in the preparation of calcified coronary lesions before implantation of a coronary endoprothesis
Study: NCT06058910

Intervention type: DIAGNOSTIC_TEST
Intervention: Bilistick System 2.0 point-of-care testing device
Description: The routine standard-of-care blood sample collection involves a 0.5 milliliter whole blood draw by the heel stick method for bilirubin assessments under current reference clinical methodology for total bilirubin. An additional 0.035 milliliter of whole blood will be collected for measurement in the point-of-care Bilistick System 2.0 (Bilistick point-of-care testing device). The resulting Bilistick System 2.0 data (i.e., total bilirubin) will be recorded, but will not be entered into the patients' electronic medical records or used for any diagnostic or medical decision purposes.
Study: NCT06276556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-671
Description: Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study.~Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.
Study: NCT06492733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FastWire System - Peripheral
Description: The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
Study: NCT05197426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose of specified days
Study: NCT06442046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Case Management
Description: A case manager will work with families post-discharge to ensure that youth are connected to an appropriate community support. Case managers will also work with families to identify any social needs and provide support in accessing services as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Subjects will receive a list of youth serving community service agencies and provided a recommendation to connect to them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Subjects will receive a list of youth serving community service agencies and provided a recommendation to connect to them.
Study: NCT06307340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training in Affective and Interpersonal Regulation with Narrative Therapy (STAIR-NT)
Description: Adapted version of evidence-based behavioral PTSD intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual.
Study: NCT05406232

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Undergo tumor punch biopsy

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Undergo RT